Olympic Swimmer Madi Wilson Hospitalized After Testing Positive for COVID-19: ‘Huge Wake-Up Call.’ The 27-year-old swimmer said she was hospitalized as a precaution because she has underlying chest and lung issues
Olympic swimmer Madi Wilson says she’s been hospitalized with a breakthrough case of COVID-19. The athlete, who won a gold medal in Tokyo for Australia, said that she recently tested positive and was moved into the hospital over the weekend as a precaution because she has underlying chest and lung issues.
Wilson, 27, wrote on Instagram, “I am extremely disappointed and upset not to be racing alongside my teammates in match 8 here in the ISL,” referencing the International Swimming League, in which she competes with Los Angeles’ team.
“Even though I am double vaccinated and took the right precaution set in place through the ISL, I have managed to fall to this virus,” said Wilson. “It’s been a crazy few months and I believe being run down physically and mentally may have made me more susceptible. I feel extremely unlucky but I do believe this is a huge wake-up call, Covid is a serious thing and when it comes it hits very hard. I’d be stupid not to say I wasn’t scared.”
She said in her caption that she’s “lucky” to have a lot of support, which she echoed in Monday videos posted on her Instagram Story.
“Special thanks to my incredible L.A. family, you haven’t and won’t ever see a team with a bigger heart than theirs, away from the pool the most incredible compassionate group of people and in the pool we are fighting with every bit of strength,” explained Wilson in her Instagram caption.
“I can promise we will be ready to fire come semifinals!”
Wilson said in her Instagram Story video that she is grateful that she’s vaccinated, explaining that she felt it kept her from having worse coronavirus symptoms.
She also said that she will “continue to encourage people to get vaccinated.”
Double-vaxxed Olympic swimming champion Madison Wilson says she feels “extremely unlucky” to have been hospitalized with Covid-19.
Wilson is currently in Naples, Italy where she is competing with the Los Angeles Current in the International Swim League. The positive diagnosis forced her out of the I.S.L. and into a hospital bed.
Wilson (2R) won bronze with the women’s 4x200m freestyle relay team in Tokyo, and also took home gold in the Women’s 4x100m freestyle relay.
(Photo by Tom Pennington/Getty Images)
“I am extremely disappointed and upset not to be racing alongside my teammates in match 8 here in the ISL,” Wilson wrote on Instagram on Sunday evening (AEST). “I recently tested positive for Covid and yesterday was moved into hospital for further care and observation.”
Wilson says she had been following ISL protocols surrounding Covid-19 and believes that her hectic schedule may have been to blame for her contracting the virus.
“Even though I am double vaccinated and took the right precaution set in place through the ISL, I have managed to fall to this virus. It’s been a crazy few months and I believe being run down physically and mentally may have made me more susceptible,” she said.
“I feel extremely unlucky but I do believe this is a huge wake up call, Covid is a serious thing and when it comes it hits very hard.”
The third iteration of the ISL is approaching its halfway point, with Wilson’s LA Current teammates one of four teams racing as part of match eight.
The Current is composed mostly of American swimmers but two other Aussies, Bronte Campbell and Matthew Wilson, have joined Madi Wilson in the side’s ranks for 2021.
Campbell swam alongside Wilson in the 4x100m women’s freestyle team that won gold at the Tokyo Olympics. It was the second gold medal of Wilson’s Olympic career — she took out the top honour in the same event at the 2016 Games in Rio de Janeiro.
Break through cases — COVID-19 infections that occur in people who have been fully vaccinated against the virus — are rare, but possible and expected, as the vaccines are not 100% effective in preventing infections. Still, vaccinated people who test positive will likely be asymptomatic or experience a far milder illness than if they were not vaccinated. The majority of deaths from COVID-19 — around 98 to 99% — are in unvaccinated people.
Video: Jon Rahm breaks into tears after forced withdrawal
Rahm was forced to withdraw from the Memorial with a record 54-hole lead after testing positive for COVID-19. CDC and PGA Tour guidelines require 10 days of quarantine after a positive test, but the Spaniard was able to return two negative tests within 24 hours to cut that time short. Had he not recorded the negative tests, Rahm wouldn’t have been allowed to arrive at Torrey Pines until Tuesday.
“I was like, all right, at least I can go hit some balls and get ready starting a little bit earlier because otherwise today at 7 a.m. was my 10th day, and I would have had to have flown in this morning,” Rahm said. “I would have felt a little bit under-prepared. At least starting [last] Saturday, I can get on a bit of a roll.”
Rahm tested + at Muirfield Village after being flagged for contact tracing.
He would have been exempt from contact tracing had he been fully vaccinated. According to CDC guidelines, fully vaccinated is defined as 14 days after your final vaccination. “Truth is, I was vaccinated. I just wasn’t out of that 14-day period. I had started the process, and unfortunately, that’s how timing ended up being,” Rahm said.
“Looking back on it, yeah, I guess I wish I would have done it [vaccination] earlier, but thinking on scheduling purposes and having the PGA and defending Memorial, to be honest it wasn’t in my mind.
“I’m not going to lie; I was trying to just get ready for a golf tournament.
If I had done it a few days earlier, probably we wouldn’t be having these conversations right now.”
As for the fallout from his WD and the various opinions on how things should have played out, Rahm placed no blame on anyone.
RELATED: Alabama Reports More Deaths Than Births for the First Time Ever Due to COVID Pandemic
Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Abnormal liver function tests (LFTs) are reported frequently in hospitalized coronavirus disease 2019 (COVID‐19) patients. A review of the literature shows that 46% of admitted COVID‐19 patients had elevated plasma aspartate aminotransferase (AST) and 35% had elevated alanine aminotransferase (ALT) levels on admission.
Elevations of both AST and ALT are mostly below 5 times the upper reference limit and are associated with severe disease and increased inflammatory markers. AST and ALT elevations are more frequent in US patients compared to Chinese patients. Mild elevations in gamma‐glutamyltransferase (GGT), alkaline phosphatase (ALP) and total bilirubin are also reported, although less frequently.
Significant impairment of liver function or overt liver failure as the cause of death in COVID‐19 rarely occur. There is no direct evidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) hepatic infection, although a subset of hepatocytes and cholangiocytes express the host receptor utilized for cellular entry by SARS‐CoV‐2. The presence of pre‐existing liver disease in patients with elevated LFTs on admission has not been comprehensively assessed in most studies but is unlikely to account for all abnormalities in LFTs.
Although abnormal LFTs are already frequently present upon admission before the start of treatment, drug‐induced liver injury should be taken into consideration, especially after the use of acetaminophen, lopinavir/ritonavir and remdesivir, which are potentially hepatotoxic.
In conclusion, these initial observations suggest that the prevalence of abnormal LFTs is high in COVID‐19 patients, but that the clinical relevance is limited and that treatment is not required. The mechanisms underlying abnormal LFTs in COVID‐19 are likely multifactorial and related to a hyper‐inflammatory status and thrombotic microangiopathy that are observed in severe COVID‐19 disease.
Researcher: ‘We Made a Big Mistake’ on COVID-19 Vaccine –
Rights and Freedoms (wordpress.com)
In a new study, patients with COVID-19 presented with abnormal liver tests at much higher rates than suggested by earlier research. The researchers also discovered that higher levels of liver enzymes—proteins released when the liver is damaged—were associated with poorer outcomes for these patients, including ICU admission, mechanical ventilation, and death.
Previous studies in China found that approximately 15% of patients with COVID-19 had abnormal liver tests.
The new study looked retrospectively at 1,827 COVID-19 patients who were hospitalized in the Yale New Haven Health system between March and April. The researchers found that the incidence of abnormal liver tests was much higher—between 41.6% and 83.4% of patients, depending on the specific test.
In all, the researchers examined five liver tests, looking at factors such as elevations in aspartate aminotransferase (AST) and alanine transaminase (ALT), which indicate liver cell inflammation; an increase in bilirubin, which indicates liver dysfunction; and increased levels of alkaline phosphatase (ALP), which may indicate inflammation of bile ducts.
Although the researchers do not know why the incidence of abnormal liver tests was so much higher than in previous studies from China, senior author Joseph Lim, professor of medicine and director of the Yale University Viral Hepatitis Program, says other health differences between the Chinese and US populations could account for it.
“We can speculate that US patients may have an increased rate of other risk factors such as alcoholic or non-alcoholic fatty liver disease,” he says.
Liver disease is widespread in the US population. “In the US, close to one-third of people have fatty liver disease, and several million people have chronic hepatitis B or C,” says coauthor Michael Nathanson, professor of medicine (digestive diseases), professor of cell biology, and director of the Yale Liver Center.
Because the researchers had access to patients’ health records, they were also able to look at their liver tests prior to being diagnosed with COVID-19. Approximately one-quarter of patients in the study had abnormal liver tests prior to being admitted for the virus. But regardless of whether patients came to the hospital with existing liver problems or developed them during their COVID-19-related hospitalization, the researchers observed a strong association between abnormal liver tests and the severity of the COVID-19 cases, they say.
Rather than the liver itself driving poorer outcomes in COVID-19 patients, the organ is more likely “a bystander” affected by the hyperinflammation associated with COVID-19 and by the side effects of related treatments, Nathanson says.
The study notes a relationship between drugs used to treat severe COVID-19 and liver damage, most significantly the drug tocilizumab.“We observed a strong association between the use of COVID-19 medications and abnormal liver tests,” says Lim, but adds that they could not confidently tease out that the abnormal tests were due to “drug-induced liver injury” as opposed to the disease. The researchers have additional clinical and lab-based studies underway to further understand COVID-19’s effect on liver pathology.
Everyone Needs to Read This Exhaustive COVID-19 Breakdown and Analysis! | SOTN: Alternative News, Analysis & Commentary (stateofthenation.co)
The study appears in Hepatology.
Source: Yale University
Women’s World heal your liver to outsmart Covid – Bing video
Sipping on three mugs of Green tea daily can prevent Non Alcoholic fatty liver disease, or NAFLD, plus helps shrink fat deposits by as much as 67% if you’ve already got them. Canadian investigators report. Credit goes to green tea compounds catechins, These potent antioxidants energize liver mitochondria, the tiny furnaces that soak up fats and convert them into fuel.
Also taking 3000 IUs of Vitamin D3 daily can halve the risk of NAFLD, suggest research in JGH Open, Study Co-Author Manu Mahta Ph.D., says skin only produces D-3 when exposed to strong sun. Yet you need nutrients year round because it helps your liver burn excess fats.
Me and my shadow: Is your sunshine the “right” sunshine for vitamin D production?
August 8, 2011/0 Comments/in Bone Nutrition /by Dr. Susan E. BrownWe produce vitamin D from sunlight exposure, but not all sunshine is created equal.
Only a narrow spectrum of sunlight ultraviolet radiation (UV) stimulates our body’s production of vitamin D, and it’s most intense at the equator where the sun is directly overhead. However, as you move away from the equator, UV radiation varies by season, being the most intense in the summer when the sun is high in the sky. In northern areas, the slant of the sun is such that during the winter months we produce virtually no vitamin D.
As getting vitamin D from the sun is so important, I am delighted to share with you a very simple system for estimating the Vitamin D–generating potential of your sunlight. It comes from Canadian vitamin D authority, Dr. Reinhold Vieth, who reports that all you need to do is to look at your shadow. If your shadow is shorter than you are, then you are able to produce vitamin D from this sunlight. If your shadow is longer than you are then you know you are not being exposed to that small spectrum ultraviolet radiation that allows for vitamin D production.
I tried the simple system myself here in Syracuse, New York, in mid-July:
– At 7 AM, my shadow was much taller than I am,
– by 11:30 AM, with the sun reaching directly overhead, it was very short,
– by 1:30 PM, it was even shorter,
– by 3:30 PM, the shadow was still shorter than I, but growing….
– and by 4 PM, me and my shadow were about the same size.
From past research we know that these hours around midday are
indeed the prime time for vitamin D production.
Actually this little tidbit is but one part of a very impressive vitamin D lecture Dr. Vieth recently presented at a conference in London. Oh yeah, be sure to pick a sunny day for this experiment. If it is a cloudy day, you will not see your shadow at all. For a YouTube video of this lecture http://bit.ly/quUhb7.